Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Berberine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 10/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.98 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.96 |
| ▸ | PPARD known ✓ | Q03181 | 1/20 | 0.96 |
| ▸ | BCHE | P06276 | 8/20 | 0.98 |
| ▸ | EP300 | Q09472 | 7/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.98 |
| ▸ | RAD52 | P43351 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | RXRA | P19793 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berberine SCHEMBL2874125 | 1.00 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL30420905 | 1.00 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL30833079 | 1.00 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL29749148 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL15936397 | 0.99 | ACHE (0.98) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL29396036 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL153906 | 0.99 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL25632 | 0.98 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL30153843 | 0.98 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT | |
| Berberine SCHEMBL15669190 | 0.98 | ACHE (1.00) | ACHEBCHEEP300CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2026-01-08 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-120081839-A | Berberine isoquinoline derivative, preparation method thereof and application thereof in resisting multiple myeloma | 南京中医药大学 | 2025-06-03 | — | — | CN | claimed |
| EP-4554613-A2 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2025-05-21 | — | — | EP | claimed |
| CN-119874699-A | Ternary drug organic salt and preparation method and application thereof | 闽江学院 | 2025-04-25 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-119033675-A | All-natural aggregation-induced luminescent glycyrrhizic acid active hydrogel and preparation method and application thereof | 华南理工大学 | 2024-11-29 | — | — | CN | claimed |
| WO-2024015529-A2 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-01-18 | — | — | WO | claimed |
| CN-110755610-B | Antibacterial hydrogel with aggregation-induced emission effect and preparation method thereof | 天津科技大学 | 2022-04-08 | — | — | CN | claimed |
| CN-113422156-A | Modified diaphragm material, modified diaphragm and lithium-sulfur button cell | 广东电网有限责任公司 | 2021-09-21 | — | — | CN | claimed |
| US-10806829-B2 | Antimicrobial medical devices | BECTON, DICKINSON AND COMPANY (US) | 2020-10-20 | — | — | US | claimed |
| CN-110755610-A | Antibacterial hydrogel with aggregation-induced emission characteristic and preparation method thereof | 天津科技大学 | 2020-02-07 | — | — | CN | claimed |
| WO-2019036650-A1 | ANTIMICROBIAL MEDICAL DEVICES | BECTON, DICKINSON AND COMPANY (US) | 2019-02-21 | — | — | WO | claimed |
| US-20190054213-A1 | Antimicrobial Medical Devices | BECTON, DICKINSON AND COMPANY | 2019-02-21 | — | — | US | claimed |
| EP-0527186-A4 | — | UNIV ILLINOIS (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0527186-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | The Board of Trustees for the University of Illinois (US) | 1993-02-17 | — | — | EP | claimed |
| WO-1991016820-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1991-11-14 | — | — | WO | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-1991016820-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | BCL3, BCL9, BCL9L | ACHE 4205/4885CHRM1 4753/4885DRD2 2898/4885 |
| US-20190054213-A1 | Antimicrobial Medical Devices | PPOX, CUTA, PPIA | ACHE 3060/4885CHRM1 3943/4885DRD2 3027/4885 |
| US-10806829-B2 | Antimicrobial medical devices | PPOX, CUTA, PPIA | ACHE 3060/4885CHRM1 3943/4885DRD2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.